DE69816082T2 - Phosphatbindende polymerzubereitungen - Google Patents
Phosphatbindende polymerzubereitungen Download PDFInfo
- Publication number
- DE69816082T2 DE69816082T2 DE69816082T DE69816082T DE69816082T2 DE 69816082 T2 DE69816082 T2 DE 69816082T2 DE 69816082 T DE69816082 T DE 69816082T DE 69816082 T DE69816082 T DE 69816082T DE 69816082 T2 DE69816082 T2 DE 69816082T2
- Authority
- DE
- Germany
- Prior art keywords
- phosphate
- binding polymer
- less
- tablet
- particle size
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229920000642 polymer Polymers 0.000 title claims abstract description 95
- 102000006335 Phosphate-Binding Proteins Human genes 0.000 title claims abstract description 89
- 108010058514 Phosphate-Binding Proteins Proteins 0.000 title claims abstract description 89
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 239000002245 particle Substances 0.000 claims abstract description 37
- 229920002678 cellulose Polymers 0.000 claims abstract description 25
- 239000001913 cellulose Substances 0.000 claims abstract description 25
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims description 11
- 229920000083 poly(allylamine) Polymers 0.000 claims description 5
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 claims description 4
- 201000005991 hyperphosphatemia Diseases 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 238000004132 cross linking Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- 238000000227 grinding Methods 0.000 claims description 2
- -1 hydroxypropoxyl residues Chemical class 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 abstract description 13
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract description 13
- 239000010452 phosphate Substances 0.000 abstract description 13
- 238000003756 stirring Methods 0.000 abstract description 4
- 230000002378 acidificating effect Effects 0.000 abstract description 3
- 230000007935 neutral effect Effects 0.000 abstract description 3
- 230000001105 regulatory effect Effects 0.000 abstract description 3
- 230000002496 gastric effect Effects 0.000 abstract description 2
- 230000033001 locomotion Effects 0.000 abstract description 2
- 239000003826 tablet Substances 0.000 description 61
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000000654 additive Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 230000003068 static effect Effects 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000003825 pressing Methods 0.000 description 5
- 230000004580 weight loss Effects 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 239000007941 film coated tablet Substances 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229920001268 Cholestyramine Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 229940031705 hydroxypropyl methylcellulose 2910 Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- YIXJRHPUWRPCBB-UHFFFAOYSA-N magnesium nitrate Chemical compound [Mg+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O YIXJRHPUWRPCBB-UHFFFAOYSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 125000002924 primary amino group Chemical class [H]N([H])* 0.000 description 2
- 125000000467 secondary amino group Chemical class [H]N([*:1])[*:2] 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- AJTVSSFTXWNIRG-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanesulfonic acid Chemical compound OCC[NH+](CCO)CCS([O-])(=O)=O AJTVSSFTXWNIRG-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010011953 Decreased activity Diseases 0.000 description 1
- 229920003114 HPC-L Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- IJBYVKWTVVYTPL-UHFFFAOYSA-M calcium;2-ethenylbenzenesulfonate Chemical compound [Ca+2].[O-]S(=O)(=O)C1=CC=CC=C1C=C IJBYVKWTVVYTPL-UHFFFAOYSA-M 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 229950008138 carmellose Drugs 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000007542 hardness measurement Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229940059939 kayexalate Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940073095 questran Drugs 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 229940006186 sodium polystyrene sulfonate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000002522 swelling effect Effects 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8658197 | 1997-04-04 | ||
| JP8658197 | 1997-04-04 | ||
| PCT/JP1998/001536 WO1998044933A1 (en) | 1997-04-04 | 1998-04-03 | Phosphate-binding polymer preparations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69816082D1 DE69816082D1 (de) | 2003-08-07 |
| DE69816082T2 true DE69816082T2 (de) | 2004-04-15 |
Family
ID=13890981
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69816082T Expired - Lifetime DE69816082T2 (de) | 1997-04-04 | 1998-04-03 | Phosphatbindende polymerzubereitungen |
| DE69837945T Expired - Lifetime DE69837945T2 (de) | 1997-04-04 | 1998-04-03 | Tablette, umfassend ein phosphatbindendes Polymer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69837945T Expired - Lifetime DE69837945T2 (de) | 1997-04-04 | 1998-04-03 | Tablette, umfassend ein phosphatbindendes Polymer |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US6383518B1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP0997148B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2009173687A (cg-RX-API-DMAC7.html) |
| KR (1) | KR100456202B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN1180782C (cg-RX-API-DMAC7.html) |
| AT (2) | ATE244013T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU726142B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2286003C (cg-RX-API-DMAC7.html) |
| CY (1) | CY1106823T1 (cg-RX-API-DMAC7.html) |
| DE (2) | DE69816082T2 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1304104T3 (cg-RX-API-DMAC7.html) |
| ES (2) | ES2287215T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT1304104E (cg-RX-API-DMAC7.html) |
| TW (1) | TW592727B (cg-RX-API-DMAC7.html) |
| WO (1) | WO1998044933A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9720061D0 (en) | 1997-09-19 | 1997-11-19 | Crosfield Joseph & Sons | Metal compounds as phosphate binders |
| JP3718341B2 (ja) | 1998-05-12 | 2005-11-24 | 信越化学工業株式会社 | 低置換度ヒドロキシプロピルセルロースとその製造方法 |
| TW568788B (en) * | 1998-10-12 | 2004-01-01 | Chugai Pharmaceutical Co Ltd | Polymer combining with phosphoric acid and preparation containing the same |
| US6733780B1 (en) | 1999-10-19 | 2004-05-11 | Genzyme Corporation | Direct compression polymer tablet core |
| US20020054903A1 (en) * | 1999-10-19 | 2002-05-09 | Joseph Tyler | Direct compression polymer tablet core |
| HUP0203334A2 (hu) * | 1999-10-19 | 2003-02-28 | Geltex Pharmaceuticals, Inc. | Közvetlen kompresszióval előállított polimer tabletta magok |
| US6680069B1 (en) | 1999-11-09 | 2004-01-20 | Shin-Etsu Chemical Co., Ltd. | Low-substituted hydroxypropyl cellulose and process for manufacturing the same |
| JP3552160B2 (ja) | 2000-01-14 | 2004-08-11 | 信越化学工業株式会社 | 低置換度ヒドロキシプロピルセルロース粒子の形成方法 |
| US6710162B2 (en) | 2001-02-16 | 2004-03-23 | Genzyme Corporation | Method of drying a material having a cohesive phase |
| WO2002085379A1 (en) * | 2001-04-18 | 2002-10-31 | Geltex Pharmaceuticals, Inc. | Method for improving vascular access in patients with vascular shunts |
| AU2002257145B2 (en) | 2001-04-18 | 2005-06-02 | Genzyme Corporation | Method for lowering serum glucose |
| MXPA03009572A (es) | 2001-04-18 | 2004-02-12 | Genzyme Corp | Formas de polialilamina con bajo contenido en sal. |
| FR2827771B1 (fr) * | 2001-07-25 | 2003-10-24 | Apis Spheromont | Formulation et procede de preparation de spheroides pouvant etre fortement titres et a dispersion rapide |
| US6600011B2 (en) | 2001-10-09 | 2003-07-29 | Genzyme Corporation | Process for purification and drying of polymer hydrogels |
| TWI231760B (en) * | 2001-12-20 | 2005-05-01 | Chugai Pharmaceutical Co Ltd | Coated lozenge and manufacturing method thereof |
| US7767768B2 (en) | 2003-11-03 | 2010-08-03 | Ilypsa, Inc. | Crosslinked amine polymers |
| US7608674B2 (en) | 2003-11-03 | 2009-10-27 | Ilypsa, Inc. | Pharmaceutical compositions comprising cross-linked small molecule amine polymers |
| US7459502B2 (en) | 2003-11-03 | 2008-12-02 | Ilypsa, Inc. | Pharmaceutical compositions comprising crosslinked polyamine polymers |
| US7449605B2 (en) * | 2003-11-03 | 2008-11-11 | Ilypsa, Inc. | Crosslinked amine polymers |
| US7335795B2 (en) | 2004-03-22 | 2008-02-26 | Ilypsa, Inc. | Crosslinked amine polymers |
| US7385012B2 (en) | 2003-11-03 | 2008-06-10 | Ilypsa, Inc. | Polyamine polymers |
| US20060177415A1 (en) * | 2004-11-01 | 2006-08-10 | Burke Steven K | Once a day formulation for phosphate binders |
| US7985418B2 (en) | 2004-11-01 | 2011-07-26 | Genzyme Corporation | Aliphatic amine polymer salts for tableting |
| EP1869090A1 (en) * | 2005-03-16 | 2007-12-26 | Council Of Scientific And Industrial Research | An improved process for the preparation of crosslinked polyallylamine polymer. |
| JP2009507019A (ja) | 2005-09-02 | 2009-02-19 | ジェンザイム・コーポレーション | リン酸塩を除去する方法およびそれに使用される重合体 |
| DK1924246T3 (en) | 2005-09-15 | 2016-01-18 | Genzyme Corp | PORTION LETTER DEFINITION OF amine polymers |
| GB0601899D0 (en) * | 2006-01-31 | 2006-03-08 | Ineos Silicas Ltd | Compositions |
| MY157620A (en) | 2006-01-31 | 2016-06-30 | Cytochroma Dev Inc | A granular material of a solid water-soluble mixed metal compound capable of binding phosphate |
| DK1818048T3 (da) * | 2006-02-14 | 2009-04-20 | Teva Pharma | Farmaceutiske formuleringer af alifatiske aminpolymerer og metoder til deres fremstilling |
| CN101404982A (zh) | 2006-02-14 | 2009-04-08 | 特瓦制药工业有限公司 | 脂族胺聚合物的药物制剂和它们的制造方法 |
| EP2016114A2 (en) * | 2006-05-05 | 2009-01-21 | Genzyme Corporation | Amine condensation polymers as phosphate sequestrants |
| US20100124542A1 (en) * | 2006-07-18 | 2010-05-20 | Genzyme Corporation | Amine dendrimers |
| RU2009111853A (ru) | 2006-09-01 | 2010-10-10 | Юсв Лимитед (In) | Способ получения гидрохлорида севеламера и его лекарственной формы |
| US7964182B2 (en) | 2006-09-01 | 2011-06-21 | USV, Ltd | Pharmaceutical compositions comprising phosphate-binding polymer |
| BRPI0717545A2 (pt) | 2006-09-29 | 2013-10-22 | Gezyme Corp | Composição farmacêutica, método para tratar uma doença, polímero de amida, rede de polímero, e, método para preparar um polímero de amida |
| BRPI0720234A2 (pt) * | 2006-12-14 | 2013-12-24 | Genzyme Corp | Composição farmacêutica |
| JP2010519298A (ja) * | 2007-02-23 | 2010-06-03 | ゲンズイメ コーポレーション | アミンポリマー組成物 |
| US20100196305A1 (en) * | 2007-03-08 | 2010-08-05 | Dhal Pradeep K | Sulfone polymer compositions |
| EP2152277A1 (en) * | 2007-04-27 | 2010-02-17 | Genzyme Corporation | Amido-amine dendrimer compositions |
| GB0714670D0 (en) | 2007-07-27 | 2007-09-05 | Ineos Healthcare Ltd | Use |
| WO2009034540A1 (en) * | 2007-09-11 | 2009-03-19 | Ranbaxy Laboratories Limited | Pharmaceutical composition of sevelamer |
| GB0720220D0 (en) | 2007-10-16 | 2007-11-28 | Ineos Healthcare Ltd | Compound |
| EP2217215A1 (en) * | 2007-12-14 | 2010-08-18 | Genzyme Corporation | Coated pharmaceutical compositions |
| WO2009154747A1 (en) * | 2008-06-20 | 2009-12-23 | Genzyme Corporation | Pharmaceutical compositions |
| DE102008030046A1 (de) | 2008-06-25 | 2009-12-31 | Ratiopharm Gmbh | Kompaktiertes Polyallylamin-Polymer |
| RU2011134847A (ru) * | 2009-01-22 | 2013-02-27 | Юсв Лимитед | Фармацевтические композиции, содержащие фосфатсвязывающий полимер |
| US20100330175A1 (en) * | 2009-06-24 | 2010-12-30 | Jobdevairakkam Christopher N | Cross-linked polyallylamine tablet core |
| WO2010149794A2 (en) | 2009-06-26 | 2010-12-29 | Combino Pharm, S.L. | Novel pharmaceutical composition comprising poly (allylamin-co-n,n'-diallyl- 1,3-diamino-2-hydroxypropane) |
| GB0913525D0 (en) | 2009-08-03 | 2009-09-16 | Ineos Healthcare Ltd | Method |
| EP2490675B1 (en) * | 2009-10-22 | 2019-01-23 | Synthon B.V. | Pharmaceutical compositions of sevelamer |
| GB201001779D0 (en) | 2010-02-04 | 2010-03-24 | Ineos Healthcare Ltd | Composition |
| EP2545907A1 (en) | 2011-07-15 | 2013-01-16 | Combino Pharm, S.L. | Aqueous wet granulation process for cross-linked polyallylamine polymers |
| MA41202A (fr) | 2014-12-18 | 2017-10-24 | Genzyme Corp | Copolymères polydiallymine réticulé pour le traitement du diabète de type 2 |
| US20180015119A1 (en) * | 2015-02-23 | 2018-01-18 | Amneal Pharmaceuticals Company Gmbh | Process for granulating sevelamer carbonate |
| BR112019013364A2 (pt) | 2016-12-28 | 2020-04-14 | Fujifilm Corp | emulsão de polímero contendo átomo de nitrogênio ou sal do mesmo, método de produção para o mesmo e método de produção para partículas |
| EP3698799B1 (en) | 2017-10-16 | 2022-01-26 | FUJIFILM Corporation | Hyperphosphatemia treatment agent |
| CN111246857A (zh) * | 2017-10-16 | 2020-06-05 | 富士胶片株式会社 | 高磷血症治疗剂及粒子 |
| JP2019182818A (ja) * | 2018-04-17 | 2019-10-24 | ライオン株式会社 | 舌苔除去用の口腔内崩壊錠及び舌苔除去方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6090243A (ja) | 1983-10-25 | 1985-05-21 | Nitto Boseki Co Ltd | 小球状モノアリルアミン橋かけ重合体の製造方法 |
| US4631305A (en) * | 1985-03-22 | 1986-12-23 | The Upjohn Company | Polymeric material as a disintegrant in a compressed tablet |
| ES2039226T3 (es) | 1986-12-30 | 1993-09-16 | American Cyanamid Company | Procedimiento para preparar composiciones que contienen policarbofil. |
| US4956182A (en) * | 1989-03-16 | 1990-09-11 | Bristol-Myers Company | Direct compression cholestyramine tablet and solvent-free coating therefor |
| JPH02286621A (ja) | 1989-04-26 | 1990-11-26 | Mitsubishi Kasei Corp | 経口コレステロール低下剤 |
| JPH0413627A (ja) | 1990-04-27 | 1992-01-17 | Mitsubishi Kasei Corp | 経口コレステロール低下剤 |
| JP2609022B2 (ja) | 1990-11-29 | 1997-05-14 | 北陸製薬株式会社 | ポリカルボフィルカルシウム含有製剤 |
| JPH06157325A (ja) | 1992-11-30 | 1994-06-03 | Mitsubishi Kasei Corp | 経口コレステロール低下剤 |
| TW272942B (cg-RX-API-DMAC7.html) | 1993-02-10 | 1996-03-21 | Takeda Pharm Industry Co Ltd | |
| US5667775A (en) | 1993-08-11 | 1997-09-16 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
| US5496545A (en) * | 1993-08-11 | 1996-03-05 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
| WO1996021454A1 (en) * | 1995-01-12 | 1996-07-18 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
| JP3836893B2 (ja) | 1995-01-24 | 2006-10-25 | アボットジャパン株式会社 | ポリカルボフィルカルシウム含有製剤 |
| TW438608B (en) | 1995-08-02 | 2001-06-07 | Hisamitsu Pharmaceutical Co | A tablet containing anion exchange resin |
| JP3389493B2 (ja) * | 1997-04-04 | 2003-03-24 | 中外製薬株式会社 | リン酸結合性ポリマー製剤 |
-
1998
- 1998-03-19 TW TW087104092A patent/TW592727B/zh not_active IP Right Cessation
- 1998-04-03 WO PCT/JP1998/001536 patent/WO1998044933A1/ja not_active Ceased
- 1998-04-03 AU AU65223/98A patent/AU726142B2/en not_active Expired
- 1998-04-03 DE DE69816082T patent/DE69816082T2/de not_active Expired - Lifetime
- 1998-04-03 EP EP98911187A patent/EP0997148B1/en not_active Expired - Lifetime
- 1998-04-03 DE DE69837945T patent/DE69837945T2/de not_active Expired - Lifetime
- 1998-04-03 PT PT02025683T patent/PT1304104E/pt unknown
- 1998-04-03 CN CNB988046245A patent/CN1180782C/zh not_active Expired - Lifetime
- 1998-04-03 ES ES02025683T patent/ES2287215T3/es not_active Expired - Lifetime
- 1998-04-03 CA CA002286003A patent/CA2286003C/en not_active Expired - Lifetime
- 1998-04-03 AT AT98911187T patent/ATE244013T1/de active
- 1998-04-03 US US09/381,506 patent/US6383518B1/en not_active Expired - Lifetime
- 1998-04-03 EP EP02025683A patent/EP1304104B1/en not_active Expired - Lifetime
- 1998-04-03 KR KR10-1999-7009058A patent/KR100456202B1/ko not_active Expired - Lifetime
- 1998-04-03 ES ES98911187T patent/ES2201463T3/es not_active Expired - Lifetime
- 1998-04-03 AT AT02025683T patent/ATE364377T1/de active
- 1998-04-03 DK DK02025683T patent/DK1304104T3/da active
-
2002
- 2002-03-06 US US10/090,622 patent/US6696087B2/en not_active Expired - Lifetime
-
2007
- 2007-08-23 CY CY20071101107T patent/CY1106823T1/el unknown
-
2009
- 2009-05-15 JP JP2009118371A patent/JP2009173687A/ja not_active Withdrawn
-
2012
- 2012-10-18 JP JP2012230662A patent/JP5681156B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CY1106823T1 (el) | 2012-05-23 |
| JP2013010803A (ja) | 2013-01-17 |
| ATE244013T1 (de) | 2003-07-15 |
| KR100456202B1 (ko) | 2004-11-09 |
| KR20010005980A (ko) | 2001-01-15 |
| EP1304104A3 (en) | 2003-11-12 |
| HK1027506A1 (en) | 2001-01-19 |
| DE69837945T2 (de) | 2008-02-21 |
| PT1304104E (pt) | 2007-07-27 |
| TW592727B (en) | 2004-06-21 |
| EP0997148A4 (en) | 2000-05-03 |
| EP1304104B1 (en) | 2007-06-13 |
| US6696087B2 (en) | 2004-02-24 |
| EP0997148B1 (en) | 2003-07-02 |
| CA2286003C (en) | 2007-06-05 |
| HK1055387A1 (en) | 2004-01-09 |
| JP2009173687A (ja) | 2009-08-06 |
| CN1254287A (zh) | 2000-05-24 |
| DK1304104T3 (da) | 2007-07-16 |
| US6383518B1 (en) | 2002-05-07 |
| EP1304104A2 (en) | 2003-04-23 |
| EP0997148A1 (en) | 2000-05-03 |
| DE69837945D1 (de) | 2007-07-26 |
| ES2287215T3 (es) | 2007-12-16 |
| AU726142B2 (en) | 2000-11-02 |
| US20020122786A1 (en) | 2002-09-05 |
| CN1180782C (zh) | 2004-12-22 |
| ES2201463T3 (es) | 2004-03-16 |
| CA2286003A1 (en) | 1998-10-15 |
| WO1998044933A1 (en) | 1998-10-15 |
| AU6522398A (en) | 1998-10-30 |
| ATE364377T1 (de) | 2007-07-15 |
| JP5681156B2 (ja) | 2015-03-04 |
| DE69816082D1 (de) | 2003-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69816082T2 (de) | Phosphatbindende polymerzubereitungen | |
| DE69431247T2 (de) | Oxybutyninformulierungen mit gesteuerter freisetzung | |
| EP0582186B1 (de) | Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung | |
| DE69523438T2 (de) | Orale metoprolol-dosisform des typs "einmal täglich" | |
| AT398165B (de) | Verfahren zur herstellung einer pharmazeutischen kapsel zur oralen verabreichung mit verzögerter wirkstofffreisetzung bzw. kombinierter verzögerter/rascher wirkstofffreisetzung | |
| AT391078B (de) | Verfahren zur herstellung von granulaten bzw. von presstabletten mit regulierter wirkstoffabgabe | |
| DE69434479T2 (de) | Tramadolhaltiges Arzneimittel mit gesteuerter Wirkstoffabgabe | |
| DE69428853T2 (de) | Heterodisperse Hydrogelsysteme zur verzögerten Freisetzung unlöslicher Arzneistoffe | |
| DE69619139T2 (de) | Ein amonenaustauscherharz enthaltende tabletten | |
| DE60133538T2 (de) | Formulierung und tabletten mit guaifenesin mit verzögerter freisetzung | |
| DE3309516C2 (cg-RX-API-DMAC7.html) | ||
| DE3246492C2 (de) | Verfahren zur Herstellung therapeutischer Präparate auf der Basis von Hydroxypropylmethylzellulose mit verlängertem Freisetzungsverlauf | |
| DE4329794C2 (de) | Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung | |
| DE69315257T2 (de) | Simethicon enthaltende Arzneimittel zur Behandlung gastrointestinaler Störungen | |
| EP0173210B1 (de) | Pellet-Zubereitung | |
| DE60038536T2 (de) | Matrixsystem mit verzögerter freisetzung für hochlösliche wirkstoffe | |
| DE69816951T2 (de) | Zubereitung enthaltend Cefaclor oder Cephalexin mit modifizierter Freisetzungsmatrix | |
| DE60017285T2 (de) | Direktkomprimierter tablettenkern auf polymerbasis | |
| DE69530759T2 (de) | Filmbeschichtete tablette, die paracetamol und domperidone enthält | |
| DE60210139T2 (de) | Pharmazeutische zusammensetzungen enthaltend tegaserod | |
| EP1435915A1 (de) | Orale darreichungsformen für propiverin oder seinen pharmazeutisch annehmbaren salzen mit verlängerter wirkstofffreisetzung | |
| DE69814850T2 (de) | Paracetamol enthaltende schlickbare tablette | |
| DE69227773T2 (de) | Tabletten mit hohem gehalt an colestipolhydrochlorid | |
| DE69111574T2 (de) | Polycarbophil-Kalzium enthaltendes Arzneimittel. | |
| DE69712033T2 (de) | Anionenaustauscherharze enthaltende tabletten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |